Symbol: EKO / TSX
MONTREAL, Jan. 19 /CNW Telbec/ - Noveko International Inc. ("the Company") is pleased to announce that its subsidiary, Noveko Trading 2008 LLC, has concluded an exclusive distribution agreement with Israeli-based Zer Hitech (1976) Ltd. ("Zer Hitech"), a subsidiary of the ZER Group, a leading biotechnology company. The agreement covers the distribution of Noveko(TM) antimicrobial masks and respirators, Microban(R) hand sanitizers, air filters incorporating the Noveko(TM) antimicrobial filtration technology to hospitals and commercial buildings, as well as Epurair(TM) MA-1 HEPA air purifiers within the State of Israel. This agreement crystallizes an already existing business relationship and has an initial term of three years.
Following a thorough process, Zer Hitech was awarded by SAREL a contract to supply Noveko(TM) antimicrobial masks to health establishments throughout Israel. Further to this award, deliveries of masks to the Israeli market have already started. SAREL is Israel's largest privately-owned supplier of goods and services to healthcare and medical institutions, handling over 48,000 healthcare-related products. It also acts as the official purchaser for the Israeli Ministry of Health.
Moreover, filters incorporating the Noveko(TM) antimicrobial filtration technology will soon be installed, through Zer Hitech, in a Tel Aviv hospital where trials will then be conducted.
"We are happy to be formalizing and strengthening our relationship with Zer Hitech, an ideal partner to promote and market our suite of antimicrobial technologies. We believe that this partnership, which is already bearing fruit, will also provide Noveko with additional long-term benefits as we are gaining a strong foothold in a country that has earned a reputation for being an international leader in the medical field. Furthermore, Zer Hitech's global network of distributors should facilitate our access to other countries," stated Mr. Alain Bolduc, President and Chief Operating Officer of the Company.
Mr. Uri Zer, Partner and Senior Vice President of Zer Hitech added: "We are convinced that Noveko's advanced patented technologies are a unique, major breakthrough helping to provide a healthier and safer environment. We believe that in a few years, the Noveko(TM) technology will be generally accepted as an unmatched air filtration solution in the market. Beyond their distinctive antimicrobial advantages, filters incorporating the Noveko(TM) technology offer an environmentally responsible solution with superior filtration effectiveness enabling significant energy savings. As well, we are actively striving to make the mobile Epurair(TM) MA-1 HEPA the golden standard for air purifiers in Israel."
Founded in 1976, Zer Group is a leading biotechnology company. Its affiliate, Zer Hitech, concentrates on fertility and infectious disease products. In addition, it represents leading companies in the field of medical supplies. Through Zer Laboratories, Zer Group also has a network of medical laboratories servicing hospitals, private laboratories and medical institutions throughout Israel. The group is currently expanding the scope of its activities.
Noveko International Inc. offers innovative solutions in the environmental and medical fields worldwide. Through its subsidiaries, the Company specializes primarily in the following business segments: the development, manufacturing and marketing of derivative products from its patented antimicrobial filtration technology, including air filters, surgical masks and respirators, along with other products with antibacterial properties such as Microban(R) brand hand sanitizers - and the development, manufacturing and marketing of medical equipment, primarily portable real-time ultrasound scanners for use in human and veterinary medicine.
Certain statements set forth in this press release constitute forward-looking statements. In some cases, these statements are identified by the use of terms such as "may", "could", "might", "intend", "should", "expect", "project", "plan", "believe", "estimate" or other comparable variants. These statements are based on the information available at the time they are written, on assumptions made by management and on the expectations of management, acting in good faith, regarding future events, including those relating to economic conditions, fluctuations in exchange rates and operating expenses, and the absence of unusual events entailing supplementary expenditures. Although management considers these assumptions and expectations reasonable based on the information available at the time they are written, they could prove inaccurate. Forward-looking statements are also subject, by their very nature, to known and unknown risks and uncertainties such as those related to the industry, acquisitions, labor relations, credit, key officers, supply and product liability. The actual results of Noveko International Inc. could differ materially from those indicated or underlying these forward-looking statements. The reader is therefore recommended not to unduly rely on these forward-looking statements. Forward-looking statements do not reflect the potential impact of special items, any business combination or any other transaction that may be announced or occur subsequent to the date hereof. Unless otherwise required under securities laws, the Company does not intend and undertakes no obligation to update or revise the forward-looking statements to account for new information, new events or new circumstances.
SOURCE Noveko International Inc.
For further information: For further information: Chantal Vennat, Director, Investor Relations and Corporate Communications, Noveko International Inc., (514) 875-0606; http://www.noveko.com